NBY - NovaBay Pharmaceuticals, Inc.
Chart Events
Momentum
Performance Outlook
- Short Term2W - 6W
- Mid Term6W - 9M
- Long Term9M+
| Previous Close | 1.1500 |
| Open | 1.1400 |
| Bid | 1.1300 x 1400 |
| Ask | 1.1500 x 4000 |
| Day's Range | 1.1200 - 1.1900 |
| 52 Week Range | 0.2400 - 1.8500 |
| Volume | 1,779,483 |
| Avg. Volume | 4,469,363 |
| Market Cap | 37.716M |
| Beta (5Y Monthly) | 3.92 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.3230 |
| Earnings Date | Aug 05, 2020 - Aug 10, 2020 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 2.25 |
Fair Value
Related Research
- Business Wire
NovaBay Pharmaceuticals Issues Letter to Stockholders
NovaBay Pharmaceuticals CEO Justin Hall issues Letter to Stockholders
- Business Wire
NovaBay Pharmaceuticals Reports First Quarter 2020 Financial Results
NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY) reports financial results for the three months ended March 31, 2020 and provides a business update.
- Business Wire
CORRECTING and REPLACING NovaBay Pharmaceuticals Appoints Andrew D. Jones Chief Financial Officer
Please replace the release with the following revised version, which includes a change in the effective date in the first paragraph, first sentence to May 4, 2020.
- Business Wire
NovaBay Pharmaceuticals to Hold First Quarter 2020 Conference Call on May 7, 2020
NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY), a medical device company based in the San Francisco Bay Area, announces that it will report first quarter 2020 financial results after market close on Thursday, May 7, 2020 and will hold an investment community conference call that day.
- Business Wire
NovaBay Pharmaceuticals Signs Agreement to Distribute COVID-19 Antibody Rapid Point-of-Care Test to U.S. Healthcare Professionals
NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY) announces an agreement with Shenzhen Microprofit Biotech Co., Ltd. to become the exclusive U.S. distributor of a rapid, finger prick test to determine the presence of COVID-19 or a potential indication of antibody immunity to COVID-19. The fluorecare® SARS-CoV-2 IgG & IgM Antibody Combined (colloidal gold chromatographic immunoassay) Test Kit is a point-of-care test to be administered by healthcare professionals. The test uses a drop of blood for the detection of COVID-19 antibodies with results available in approximately 10 minutes.
- Business Wire
NovaBay Pharmaceuticals Reports 2019 Fourth Quarter and Full Year Financial Results
NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY), a biopharmaceutical company focusing on commercializing Avenova® for the domestic eye care market, reports financial results for the three and 12 months ended December 31, 2019 and provides a business update.
- ACCESSWIRE
NovaBay Pharmaceuticals, Inc. to Host Earnings Call
NEW YORK, NY / ACCESSWIRE / March 26, 2020 / NovaBay Pharmaceuticals, Inc. (AMEX:NBY) will be discussing their earnings results in their 2019 Fourth Quarter Earnings call to be held on March 26, 2020 at ...
- Business Wire
NovaBay Pharmaceuticals Announces the Availability of KN95 Disposable Masks on Avenova.com
NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY) announces the availability of KN95 disposable air filter masks on the Company’s website Avenova.com. The masks are being sold at a price of $59.99 for a package containing 10 masks or $149.99 for a package containing 30 masks. KN95-rated masks are effective at filtering out at least 95% of airborne particles, including microorganisms, dust, pollen and air pollution.
- Business Wire
NovaBay Pharmaceuticals Unveils Refreshed Consumer Branding for Online Sales of Avenova® Antimicrobial Lid & Lash Solution
NovaBay Pharmaceuticals Unveils Refreshed Consumer Branding for Online Sales of Avenova® Antimicrobial Lid & Lash Solution
- Business Wire
NovaBay Pharmaceuticals to Hold 2019 Fourth Quarter and Full Year Conference Call on March 26, 2020
NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY), a biopharmaceutical company focusing on commercializing Avenova® for the domestic eye care market, announces that it will report 2019 fourth quarter and full year financial results after market close on Thursday, March 26, 2020 and will hold an investment community conference call that day.
- Market Exclusive
Market Morning: Prorogation Ruled Rogue, High Demand for Fed Repo, New Breast Cancer Tests
British High Court Rules Against Johnson Parliament Prorogation Apparently, proroguing Parliament was not Boris Johnson’s prerogative. The British high court ruled today that the Prime Minister acted unlawfully in suspending Parliament until October 14th, and that he misled the Queen in advising that Parliament should be suspended. Johnson is now facing calls to resign, which […]The post Market Morning: Prorogation Ruled Rogue, High Demand for Fed Repo, New Breast Cancer Tests appeared first on Market Exclusive.
- GlobeNewswire
NovaBay Pharmaceuticals Announces Pricing of $2.7 Million Private Placement of Preferred Stock and Accompanying Warrants to Purchase Common Stock
The closing of the sale of the securities is expected to take place on or about August 13, 2019, subject to the satisfaction of customary closing conditions. The preferred stock, the common stock convertible from the preferred stock, the accompanying warrants and the common stock issuable upon exercise of the warrants will not be registered under the Securities Act of 1933, as amended (the “Securities Act”) or any state securities laws and, unless so registered, may not be offered or sold in the United States except pursuant to an applicable exemption from the registration requirements of the Securities Act and applicable state securities laws.
- GlobeNewswire
NovaBay Pharmaceuticals Announces Pricing of $4.2 Million Registered Direct Offering
NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY), a biopharmaceutical company focusing on commercializing Avenova for the domestic eye care market, today announced that it has entered into a securities purchase agreement with certain institutional investors providing for the purchase and sale of 4,198,566 shares of common stock at a price of $1.00 per share in a registered direct offering, resulting in total gross proceeds of approximately $4.2 million. The Company also agreed to issue unregistered warrants to the investors in a concurrent private placement to purchase up to one share of common stock for each share purchased with an exercise price of $1.15 per share. Ladenburg Thalmann & Co. Inc., a subsidiary of Ladenburg Thalmann Financial Services Inc., (NYSE American: LTS) is acting as exclusive placement agent for the registered direct offering and concurrent private placement.
